Another remarkable accomplishment is added: Xiamen SpaceGen has achieved a series of full - score results in the externa

Recently, in the 2026 "EML4 - ALK Fusion Gene Detection (PCR)" and "PIK3CA gene mutation Detection" external quality assessment projects organized by the National Center for Clinical Laboratories (NCCL), Xiamen SpaceGen MedLab (referred to as "Xiamen SpaceGen"), a subsidiary of SpaceGen, passed two assessments with full marks, achieving excellent results. As always, the perfect - score performance once again confirms that Xiamen SpaceGen has always supported clinicians and patients with professional and rigorous quality - control processes, ultra - high - level testing capabilities, and consistent and reliable quality.

Project results

EML4-ALK fusion gene test (PCR)

PIK3CA gene mutation detection

External Quality Assessment (EQA) is an important part of the internationally recognized total quality management of clinical laboratories and an important basis for laboratory testing quality accreditation. At present, NCCL's EQA represents the highest standard of EQA in domestic laboratories and is an important means to ensure and improve the quality of laboratory inspections.

One should never forget one's original aspiration and remain steadfast at all times.

Since its establishment, the consecutive full - score transcripts in oneEQA are the outcome of Xiamen SpaceGen's consistent adherence to the principle of “rigorous inspection and strict control”. They also objectively reflect Xiamen SpaceGen's outstanding testing proficiency and stringent quality management.

Xiamen SpaceGen will leverage its past outstanding achievements as a driving force for continuous advancement. In future work, it will continue to enhance the inspection level, continuously optimize the quality management system, and offer more accurate and reliable testing services to clinicians and patients. The company is dedicated to becoming a reliable decision - making partner in the process of cancer diagnosis and treatment.